One important metric to look for in a stock is an 80 or higher Relative Strength Rating. Insulet cleared that benchmark Friday, with a jump from 77 to 87 Friday.
Risk Management In The Stock Market: How Much Money To Invest Now
IBD's unique RS Rating measures technical performance by showing how a stock's price action over the last 52 weeks measures up against that of the other stocks in our database.
Over 100 years of market history reveals that the market's biggest winners typically have an 80 or higher RS Rating as they begin their biggest runs.
Insulet is building a consolidation with a 329.33 entry. See if the stock can break out in heavy trading.
Taking a look at top and bottom line numbers, the company has posted rising EPS growth in each of the last two reports. Top line growth has also increased over the same time frame.
Insulet holds the No. 1 rank among its peers in the Medical-Products industry group. TransMedics Group and ResMed are also among the group's highest-rated stocks.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
